Logo

OMDA

Omada Health

OMDA

Omada Health • NASDAQ
$18.73 ▲ 2.91% (+0.53)
Market Cap $1.08 B
52w High $28.40
52w Low $14.14
Dividend Yield 0%
P/E -40.72
Volume 287.20K
Outstanding Shares 57.91M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $68.03M ▲ $47.584M ▲ $-3.178M ▲ -4.671% ▲ $-0.055 ▲ $-1.819M ▲
Q2-2025 $61.371M ▲ $44.523M ▲ $-5.311M ▲ -8.654% ▲ $-0.093 ▲ $-2.865M ▲
Q1-2025 $54.963M ▲ $40.296M ▲ $-9.448M ▼ -17.19% ▲ $-0.17 ▼ $-7.041M ▼
Q4-2024 $47.978M ▲ $39.076M ▲ $-8.249M ▲ -17.193% ▲ $-0.15 ▲ $-5.874M ▲
Q3-2024 $45.515M $36.919M $-9.227M -20.272% $-0.17 $-6.851M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $198.627M ▼ $287.469M ▼ $70.123M ▼ $217.346M ▲
Q2-2025 $223.146M ▲ $302.971M ▲ $88.757M ▲ $214.214M ▲
Q1-2025 $59.397M ▼ $141.182M ▲ $82.197M ▲ $58.985M ▼
Q1-2024 $115.673M $0 $-98.922M $98.922M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.178M ▲ $10.133M ▲ $-1.987M ▼ $-32.665M ▼ $-24.519M ▼ $9.596M ▲
Q2-2025 $-5.311M ▲ $2.858M ▲ $-1.25M ▼ $162.141M ▲ $163.749M ▲ $2.587M ▲
Q1-2025 $-9.448M ▲ $-16.118M ▲ $-1.249M ▼ $372K ▼ $-16.995M ▲ $-17.367M ▲
Q1-2024 $-18.969M $-20.647M $-781K $556K $-20.872M $-21.428M

Five-Year Company Overview

Income Statement

Income Statement Revenue has been climbing at a healthy pace over the past few years, and the company is converting more of that revenue into gross profit, which suggests the basic business model is sound. However, Omada is still losing money overall. Operating and net losses remain meaningful, though they are clearly narrowing over time, which points to improving efficiency and scale. In plain terms: this looks like a classic growth-stage health tech company that is moving toward, but has not yet reached, break-even profitability.

Balance Sheet

Balance Sheet The balance sheet shows a lean, early-stage profile. Total assets and cash have been drifting down as the company funds its operations, while shareholder equity has also stepped down as losses accumulate. Debt exists but appears modest relative to the overall size of the business, which limits financial risk from leverage. The main message: Omada still has a financial cushion, but the cushion has been getting thinner, so strengthening the balance sheet over time will matter, either through improved profitability or fresh capital.

Cash Flow

Cash Flow Cash flow is negative but heading in the right direction. The company continues to use cash in its day-to-day operations, yet the outflow has been shrinking each year, which suggests improving unit economics and better cost control. Free cash flow is also negative, and because capital spending is very light, the cash burn is almost entirely tied to operating the business and growing the platform. This means Omada is not yet self-funding and remains dependent on its existing cash and potential future financing while it scales.

Competitive Edge

Competitive Edge Omada appears to have a strong position within digital chronic care. Its key strengths include an integrated, multi-condition platform, strong clinical validation, and deep relationships with employers and health plans. Billing through traditional medical claims, rather than wellness budgets, makes it feel more like part of the healthcare system than a fringe benefit, which can be a real advantage. High customer retention and multi-program adoption support the idea of a sticky offering. The main risk is a very competitive digital health landscape, with both specialized startups and larger telehealth players vying for the same clients and members.

Innovation and R&D

Innovation and R&D Innovation is a clear focal point. Omada blends human coaching with connected devices and AI tools like its digital assistant, aiming to personalize care and scale support efficiently. Its emphasis on behavioral science and clinically tested programs, along with new offerings such as GLP-1 support and “between-visit” care, helps differentiate it from more generic wellness apps. Continued investment in AI, expansion into additional chronic conditions, and deeper integration with the broader healthcare ecosystem offer upside, but they also require ongoing spending and careful execution to translate into sustainable financial returns.

Summary

Omada Health looks like a maturing digital health platform with a credible product story and an early-stage financial profile. On the positive side, revenue and gross profit are growing, losses and cash burn are trending downward, and the company appears to have real competitive advantages in clinical validation, multi-condition coverage, and integration into the medical payment system. On the risk side, the balance sheet is getting lighter, the business is still not profitable or cash-generative, and it operates in a crowded, fast-moving market. The central question going forward is whether Omada can maintain its growth and clinical edge while reaching durable profitability before its financial flexibility tightens too much.

NEWS

November 20, 2025 · 9:05 AM UTC

Omada Health to Participate in Evercore Healthcare Conference

Read more

November 18, 2025 · 7:19 AM UTC

Omada positioned as a Leader and Emerging Innovator in the SPARK Matrix™: Identity Governance and Administration, 2025 by QKS Group

Read more

November 6, 2025 · 4:10 PM UTC

Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population

Read more

November 4, 2025 · 12:00 PM UTC

Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

Read more

October 27, 2025 · 9:00 AM UTC

Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer

Read more